AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05213884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin chemotherapy
Description: cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
Study NCT05213884 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: 70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
Study NCT04725812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab Intravenous Solution
Study NCT04726748 — intervention group
Intervention type: PROCEDURE
Intervention: Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts
Description: Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.
Study NCT04726748 — intervention group
Intervention type: PROCEDURE
Intervention: Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts
Description: Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables.
Study NCT05051267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Pharmacological Methods
Description: All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
Study NCT04777929 — intervention group
Intervention type: OTHER
Intervention: test Phthalates, estrogen and progesterone
Description: test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
Study NCT04940013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Study participants are given misoprostol alone for menstrual regulation.
Study NCT05591066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFC I-PASS Intervention
Description: Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
Study NCT05591066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFC I-PASS+ Intervention
Description: PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
Study NCT06468072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressivity protocol for children with autism
Description: The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
Study NCT06468072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expressivity protocol for non-autistic children
Description: The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
Study NCT05285566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
Study NCT05285566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
Study NCT05720494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP441
Description: Oral study drug administered for up to 4 weeks
Study NCT05720494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered for up to 4 weeks
Study NCT05629234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
Study NCT06646159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink Intervention
Description: At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention.
Study NCT06410703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
Study NCT06463652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: Cervical cerclage using the McDonald technique under anaesthesia.
Study NCT06463652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Study NCT06099951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab + FOLFOXIRI
Description: Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
Study NCT06099951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy
Study NCT06121960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry
Description: Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance
Study NCT05319561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic Use Report
Description: The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings.
Study NCT06463652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Study NCT05748158 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 37 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks.
Study NCT05496959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu-177 PNT2002
Description: Given IV
Study NCT05496959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05496959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05496959 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05496959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05840315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basic intervention and nutritional intervention
Description: The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories.
Study NCT05840315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sit-to-stand
Description: First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height.
Study NCT05840315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leg press
Description: Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press.
Study NCT05840315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip abduction
Description: Third subtrial (participants 21-30):~In addition to interventions described in sub-trials 1 and 2, progressive strength training of the gluteal muscles is carried out in the form of hip abduction from a sitting position, using a hip abduction machine, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press.
Study NCT06647602 — intervention group
Intervention type: DRUG
Intervention: Euthyrox (levothyroxine)
Description: Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
Study NCT06647602 — intervention group
Intervention type: DRUG
Intervention: Cytomel (liothyronine)
Description: Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
Study NCT06471036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Champion Intervention
Description: The care champion will communicate with the patient according to an algorithm and will emphasize adherence to appropriate lipid lowering therapy, LDL-C retesting, and outpatient follow-up. The care champion will also facilitate communication of any challenges or issues with the patient's outpatient care team. Of note, the care champion will NOT be responsible for prescriptions or drug management.
Study NCT04739722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ColoSense
Description: ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Study NCT06067399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glycated hemoglobin (HbA1C)
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Study NCT06067399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RDW
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Study NCT06067399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid profile
Description: Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
Study NCT06407661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disaster Nursing course/education
Description: In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level.
Study NCT05129137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nefopam hydrochloride 30mg X2
Description: nefopam hydrochloride 30mg X2
Study NCT05129137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol 500 mg X2
Description: paracetamol 500 mg X2
Study NCT05129137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Description: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Study NCT05380544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
Study NCT05380544 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
Study NCT05036668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum oocysts (ABO809)
Description: ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1
Study NCT05731037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
Study NCT05731037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training for knee extensors
Description: The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
Study NCT06561464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EzPAP®
Description: EzPAP® is a portable, single-use respiratory exercise device that provides positive expiratory pressure during expiration while supporting respiration during inspiration. Its use has been increasing in recent years as an oxygenation device. It is portable, single-use, easy to use, well-tolerated, and cost-effective. EzPAP® helps increase functional capacity in the lungs and reduces atelectasis. With EzPAP®, an oxygen flow of 5-8 L/min reaches the patient as 35-42% fractionated oxygen, thus quadrupling the oxygen flow.
Study NCT06561464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive mechanical ventilation (NIMV)
Description: NIMV provides respiratory support during both expiration and inspiration through continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Treatment success can be monitored within the first 2 hours by the improvement in oxygenation and reduction in pCO2 levels
Study NCT04018456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
Study NCT04018456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White MTA
Description: MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
Study NCT06329687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrvaya Nasal Pump
Description: Tyrvaya Nasal Pump with Silicone Lubricant
Study NCT05138276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC
Study NCT05138276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study NCT05246189 — intervention group
Intervention type: OTHER
Intervention: Telephone Call
Description: Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire.
Study NCT04940182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221
Description: Participants will receive XC221 100 mg 2 times a day during 14 full days